Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML ...Middle East

Abstract includes previously reported data: cumulative MMR rate of 47% with 38% of patients achieving MMR by 24 weeks in mature, heavily pretreated 80 mg QD Phase 1b cohort In patients who previously received asciminib, cumulative MMR rate was 52%, with 38% of patients achieving MMR by 24...

Hence then, the article about enliven therapeutics announces oral presentation at the eha 2026 congress featuring additional positive phase 1 clinical trial data for elvn 001 in cml was published today ( Tuesday 12/05/2026 - 04:58 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML )

Also on site :

• Crocs’ 'Supportive' $30 Platform Sandals at Walmart Feel Like 'Walking on Air'
• Behind Big Oil’s first-quarter beat: The quiet rise of trading desks
• Alt-R&B Singer Cast as Jazz Age Icon in Major New Biopic